BEROMUN

This brand name is authorized in Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Lithuania, Poland, United Kingdom

Active ingredients

The drug BEROMUN contains one active pharmaceutical ingredient (API):

1 Tasonermin UNII 23CA79S88F - TASONERMIN

Tasonermin is cytotoxic or cytostatic in vitro for a variety of tumour cell lines of different histogenesis. Tasonermin affects the morphology and reduces proliferation of endothelial cells. Also, it has profound effects on cellular components of the immune system. Read about Tasonermin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BEROMUN Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L03AX11	Tasonermin	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1204861
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 99097001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 598423
Country: FR	Base de données publique des médicaments	Identifier(s): 69328782
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 346078
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1027709
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100012572